Acorda Therapeutics Stock News

Acorda Therapeutics Inc (ACOR) shares closed today at 1.7% above its 52 week low of $2.34, giving the company a market cap of $22M. The stock is currently down 42.5% year-to-date, down 45.2% over the past 12 months, and down 97.8% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 69.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 6228.0% The company's stock price performance over the past 12 months lags the peer average by 896.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

This Multiple Sclerosis market report describes the factors that contribute to the sector''s development as well as market channels. When taken in order, this Multiple Sclerosis market report starts with an introduction to the commercial chain structure and then moves

DUBLIN--(BUSINESS WIRE)--The "Multiple Sclerosis Drugs Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global multiple sclerosis drugs market is expected to grow from $21.27 billion in 2020 to $22.04 billion in 2021 at a compound annual growth rate (CAGR) of 3.6%. The market is expected to reach $25.95 billion in 2025 at a CAGR of 4%. Major players in the multiple sclerosis drugs market are Biogen, Novartis, Roche, B

"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are

DUBLIN--(BUSINESS WIRE)--The "Global Multiple Sclerosis Drugs Market 2020-2027" report has been added to ResearchAndMarkets.com''s offering. The global multiple sclerosis drugs market will reach $29.97 billion by 2027, growing by 4.3% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs. The report is based on a comprehensive research of the entire global multiple sclero

Acorda Therapeutics, Inc. (NASDAQ:ACOR) saw a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 587,000 shares, an increase of 34.9% from the October 31st total of 435,000 shares. Based on an average daily trading volume, of 142,400 shares, the days-to-cover ratio is presently 4.1 [] The post Acorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest Update appeared first on ETF Daily News .

Acorda Therapeutics Inc (ACOR) shares closed 3.9% lower than its previous 52 week low, giving the company a market cap of $27M. The stock is currently down 30.9% year-to-date, down 31.1% over the past 12 months, and down 97.7% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 6.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -893.7% The company's stock price performance over the past 12 months lags the peer average by -344.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Geode Capital Management LLC raised its stake in Acorda Therapeutics, Inc. (NASDAQ:ACOR) by 13.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 73,562 shares of the biopharmaceutical companys stock after buying an additional 8,706 shares during the quarter. Geode Capital Management LLC []

Virtu Financial LLC bought a new stake in Acorda Therapeutics, Inc. (NASDAQ:ACOR) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 10,119 shares of the biopharmaceutical companys stock, valued at approximately $48,000. Virtu Financial LLC owned 0.09% of Acorda Therapeutics as of its most recent filing with []

Acorda Therapeutics Inc (ACOR) shares closed 5.0% lower than its previous 52 week low, giving the company a market cap of $29M. The stock is currently down 25.4% year-to-date, down 27.8% over the past 12 months, and down 97.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.1%. Trading Activity Trading volume this week was 28.0% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -882.1% The company's stock price performance over the past 12 months lags the peer average by -283.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Kiromic BioPharma (NASDAQ:KRBP) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk. Insider & Institutional Ownership 22.2% of Kiromic BioPharma shares are owned by institutional investors. Comparatively, []

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q3 2021 Results - Earnings Call Transcript

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Corporate Restructuring, Management Changes

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2021 Results - Earnings Call Transcript

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2021 Financial Results